The Latest Cardiac and Vascular News
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2026 financial results. “Our team delivered healthy growth and a significant step up in profitability in the second quarter,” said Michael Carrel, President and Chief Executive Officer. “Our innovative technologies continue to prove their valu
Appointments to scale adoption of Caristo’s AI-powered cardiovascular technologies globally OXFORD, England and STAMFORD, Conn., July 23, 2026 /PRNewswire/ — Caristo Diagnostics, a global leader in AI-powered technologies for cardiovascular disease, today announced two additions to its…
Drive-side force sensing and a 1:1 motion-mimicking interface make every procedure a training-grade record of expert clinical skill KAUNAS, Lithuania, July 23, 2026 /PRNewswire/ — Sentante, the medical robotics company building a haptic, device-agnostic platform for remote vascular…
The PREVAILS study, now fully enrolled, marks a critical step toward simultaneous regulatory submissions in China and Europe for the next-generation TAVR system HANGZHOU, China, July 23, 2026 /PRNewswire/ — Venus Medtech (Hangzhou) Inc. (02500.HK) today announced that patient enrollment…
SHANGHAI and MOLNDAL, Sweden, July 22, 2026 /PRNewswire/ — Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as “Ribo”) today announce at China Pharmaceutical Innovation Conference (CPIC) in Shanghai, the positive…
Collaboration combines Evogene’s AI-driven computational chemistry platform with ELEO’s proprietary biological capabilities to accelerate the discovery of novel oral therapies targeting a multi-billion-dollar cardiovascular market opportunity REHOVOT, Israel and DAEJEON, South Korea, July…
WALTHAM, Mass.–(BUSINESS WIRE)–Affinia Therapeutics (“Affinia”), an innovative clinical-stage gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for AFTX-201 for the treatment of BAG3-associated dilated cardiomyopathy (DCM). A potential best-in-class investigational genetic m
Powered by retrospective real-world data from Dandelion Health, the American Heart Association’s AI Impact Report provides a third-party evaluation of Ultromics’ EchoGo® Heart Failure The independent assessment shows EchoGo® Heart Failure could have identified HFpEF 263 days earlier than…
DRAPER, Utah— July 15, 2026 — Xenter, Inc., the world’s first TechMed™ company that has developed a healthcare intelligence platform for diagnostic evaluation and wireless medical devices that captures Physical Intelligence™ (PI) data over the XenFi™ wireless ecosystem, today announced the successful close on June 30th of its Series B financing, raising a […]
SEATTLE & YOKNEAM, Israel–(BUSINESS WIRE)– #DRIVEWIRE–Rapid Medical FDA-cleared DRIVEWIRE 35, first steerable 0.035-inch guidewire for stroke, neurovascular and peripheral access, after 5,000 DW24 cases.
